sarizotan (EMD128130) / Newron  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sarizotan (EMD128130) / Newron
EMR 62225-018, NCT00105508 / 2004-001593-10: Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

Completed
3
506
US
Sarizotan, Placebo
EMD Serono
Parkinson's Disease, Dyskinesia
02/06
02/06
EMR 62225-019, NCT00105521: Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

Completed
3
398
US
Sarizotan, Placebo
EMD Serono
Parkinson's Disease, Dyskinesia
03/06
03/06
2004-001594-25: A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson\'s disease suffering from treatment-associated dyskinesia

 
3
48
Europe
Sarizotan, EMD128130,
Merck KGaA, MERCK KGaA
Treatment-Associated Dyskinesia in Parkinson\'s Disease
 
03/06
2005-000444-84: An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson\'s disease suffering from treatment-associated dyskinesia

 
3
53
Europe
Sarizotan hydrocholride, EMD128130,
Merck KGaA, MERCK S.P.A.
Treatment-Associated Dyskinesia in Parkinson\'s Disease
 
 
STARS, NCT02790034 / 2015-004448-20: Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Terminated
2/3
129
Europe, US, RoW
Sarizotan low dose, Sarizotan high dose, Placebo
Newron Pharmaceuticals SPA
Rett Syndrome
08/19
05/20

Download Options